Zeria/Tillotts in $100m-plus deal for CPP's FAP drug

Tillotts Pharma and its parent Zeria have acquired development and commercialization rights in Europe and Japan to a therapy for familial adenomatous polyposis (FAP) being developed by Cancer Prevention Pharmaceuticals (CPP).

Tillotts Pharma and its parent Zeria have acquired development and commercialization rights in Europe and Japan to a therapy for familial adenomatous polyposis (FAP) being developed by Cancer Prevention Pharmaceuticals (CPP).

The private US venture's combination of CPP-1X (eflornithine) and sulindac entered a 150-patient Phase III trial for the indication at...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category